{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:40:15Z","timestamp":1787244015046,"version":"build-2736575974"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"UCL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Queen Square Institute of Neurology & Cleveland Clinic London"},{"name":"UK Chief Investigator for the Abcuro study","award":["NCT05721573"],"award-info":[{"award-number":["NCT05721573"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>IBM remains an enigmatic and complex muscle disorder where a deeper understanding of disease pathomechanisms and the identification of potential genetic contributors represent an unmet need. The absence of effective treatments has spurred endeavours to reassess the interplay between degeneration, including autophagy, mitochondrial dysfunction and proteasomal dysregulation, and autoimmunity. IBM is unique among the other idiopathic inflammatory myopathies owing to its molecular signature involving highly differentiated cytotoxic T cells that evade immune regulation. This has led to a resurgence of interest in the development of immunomodulatory therapy. This review discusses the potential role of cellular immunosenescence in sustaining inflammation and\/or fibrotic remodelling observed in IBM and appraises the rationale for some potential therapeutic approaches to mitigate disease progression.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae614","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T23:20:20Z","timestamp":1730762420000},"page":"952-961","source":"Crossref","is-referenced-by-count":6,"title":["Inclusion body myositis and immunosenescence: current evidence and future perspectives"],"prefix":"10.1093","volume":"64","author":[{"given":"Nur Azizah","family":"Allameen","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Woodlands Health , Woodlands,","place":["Singapore"]},{"name":"Department of Rheumatology, University College London Hospitals NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharfaraz","family":"Salam","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-4425","authenticated-orcid":false,"given":"Venkat","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University College London Hospitals NHS Foundation Trust , London,","place":["UK"]},{"name":"Department of Rheumatology, Division of Medicine, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London , London,","place":["UK"]},{"name":"Department of Rheumatology, Division of Medicine, University College London , London,","place":["UK"]},{"name":"NIHR University College London Hospitals Biomedical Research Centre , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2025030500175247600_keae614-B1","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025030500175247600_keae614-B2","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025030500175247600_keae614-B3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00415-022-11459-3","article-title":"Inclusion body myositis: from genetics to clinical trials","volume":"270","author":"Nagy","year":"2023","journal-title":"J Neurol"},{"key":"2025030500175247600_keae614-B4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","article-title":"Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry","volume":"41","author":"Mehta","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025030500175247600_keae614-B5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/BOR.0000000000000742","article-title":"Myositis autoantibodies: recent perspectives","volume":"32","author":"Riddell","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2025030500175247600_keae614-B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500175247600_keae614-B7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 Years of progress\u2014revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"2025030500175247600_keae614-B8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ncpneuro0261","article-title":"Sporadic inclusion body myositis\u2014diagnosis, pathogenesis and therapeutic strategies","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"2025030500175247600_keae614-B9","first-page":"340","article-title":"Two emerging phenotypes of atypical inclusion body myositis: illustrative cases","volume":"41","author":"Salam","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500175247600_keae614-B10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/mus.27716","article-title":"Atypical presentations of inclusion body myositis: clinical characteristics and long-term outcomes","volume":"66","author":"Alamr","year":"2022","journal-title":"Muscle Nerve"},{"key":"2025030500175247600_keae614-B11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","article-title":"Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials","volume":"23","author":"Cortese","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"2025030500175247600_keae614-B12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jnnp-2020-325141","article-title":"Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis","volume":"92","author":"Sangha","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025030500175247600_keae614-B13","doi-asserted-by":"crossref","first-page":"101764","DOI":"10.1016\/j.berh.2022.101764","article-title":"Is it really myositis? Mimics and pitfalls","volume":"36","author":"Bhai","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025030500175247600_keae614-B14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archneur.58.8.1253","article-title":"Inclusion body myositis mimicking motor neuron disease","volume":"58","author":"Dabby","year":"2001","journal-title":"Arch Neurol"},{"key":"2025030500175247600_keae614-B15","doi-asserted-by":"crossref","first-page":"101763","DOI":"10.1016\/j.berh.2022.101763","article-title":"Muscle biopsy in myositis: what the rheumatologist needs to know","volume":"36","author":"Merve","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025030500175247600_keae614-B16","doi-asserted-by":"crossref","first-page":"101761","DOI":"10.1016\/j.berh.2022.101761","article-title":"Inclusion body myositis: the interplay between ageing, muscle degeneration and autoimmunity","volume":"36","author":"McLeish","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025030500175247600_keae614-B17","doi-asserted-by":"crossref","first-page":"e004552","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"key":"2025030500175247600_keae614-B18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2051-5960-1-29","article-title":"Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies","volume":"1","author":"Hiniker","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"2025030500175247600_keae614-B19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)62994-X","article-title":"Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers","volume":"167","author":"Fratta","year":"2005","journal-title":"Am J Pathol"},{"key":"2025030500175247600_keae614-B20","doi-asserted-by":"crossref","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025030500175247600_keae614-B21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","article-title":"The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy","volume":"72","author":"Leff","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"2025030500175247600_keae614-B22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","article-title":"Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin","volume":"43","author":"Soueidan","year":"1993","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","article-title":"Inclusion body myositis: treatment with intravenous immunoglobulin","volume":"44","author":"Amato","year":"1994","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"2025030500175247600_keae614-B26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.45.7.1302","article-title":"Inclusion body myositis: explanation for poor response to immunosuppressive therapy","volume":"45","author":"Barohn","year":"1995","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B28","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"G. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"Study","year":"2001","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"2025030500175247600_keae614-B30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B31","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"2025030500175247600_keae614-B33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"G. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","author":"Study","year":"2004","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"2025030500175247600_keae614-B35","doi-asserted-by":"crossref","first-page":"P3.161","DOI":"10.1212\/WNL.86.16_supplement.P3.161","article-title":"Interim analysis of a pilot trial of natalizumab in inclusion body myositis (P3.161)","volume":"86","author":"Saperstein","year":"2016","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"key":"2025030500175247600_keae614-B37","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030500175247600_keae614-B38","author":"Saperstein"},{"key":"2025030500175247600_keae614-B39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025030500175247600_keae614-B40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B41","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"2025030500175247600_keae614-B42","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B43","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"key":"2025030500175247600_keae614-B44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13024-023-00608-5","article-title":"The era of cryptic exons: implications for ALS-FTD","volume":"18","author":"Mehta","year":"2023","journal-title":"Mol Neurodegener"},{"key":"2025030500175247600_keae614-B45","doi-asserted-by":"crossref","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","article-title":"Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis","volume":"14","author":"Britson","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025030500175247600_keae614-B46","author":"Wilson","year":"2024"},{"key":"2025030500175247600_keae614-B47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/WCO.0000000000000129","article-title":"Sporadic inclusion body myositis: new insights and potential therapy","volume":"27","author":"Machado","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"2025030500175247600_keae614-B48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11926-014-0477-9","article-title":"Ongoing developments in sporadic inclusion body myositis","volume":"16","author":"Machado","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2025030500175247600_keae614-B49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.410160207","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis","volume":"16","author":"Engel","year":"1984","journal-title":"Ann Neurol"},{"key":"2025030500175247600_keae614-B50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.410190203","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury","volume":"19","author":"Arahata","year":"1986","journal-title":"Ann Neurol"},{"key":"2025030500175247600_keae614-B51","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052742","article-title":"Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging","volume":"25","author":"Guglielmi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025030500175247600_keae614-B53","doi-asserted-by":"crossref","first-page":"e1374","DOI":"10.1212\/WNL.0000000000200013","article-title":"Immunophenotyping of inclusion body myositis blood T and NK cells","volume":"98","author":"Goyal","year":"2022","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B54","doi-asserted-by":"crossref","first-page":"e88788","DOI":"10.1371\/journal.pone.0088788","article-title":"Th1 response and systemic treg deficiency in inclusion body myositis","volume":"9","author":"Allenbach","year":"2014","journal-title":"PLoS One"},{"key":"2025030500175247600_keae614-B55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.autrev.2019.02.003","article-title":"CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis","volume":"18","author":"Dzangu\u00e9-Tchoupou","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025030500175247600_keae614-B56","doi-asserted-by":"crossref","first-page":"e1158","DOI":"10.1212\/WNL.0000000000207596","article-title":"Imaging with PET\/CT of diffuse CD8 T-cell infiltration of skeletal muscle in patients with inclusion body myositis","volume":"101","author":"Quinn","year":"2023","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B57","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"key":"2025030500175247600_keae614-B58","doi-asserted-by":"crossref","first-page":"e1504","DOI":"10.1002\/cti2.1504","article-title":"Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models","volume":"13","author":"McLeish","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"2025030500175247600_keae614-B59","doi-asserted-by":"crossref","first-page":"e12955","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"key":"2025030500175247600_keae614-B60","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B61","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","article-title":"Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system","volume":"23","author":"Nishikai","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2025030500175247600_keae614-B62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin Immunol Immunopathol"},{"key":"2025030500175247600_keae614-B63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"2025030500175247600_keae614-B64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"2025030500175247600_keae614-B65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500175247600_keae614-B66","doi-asserted-by":"crossref","first-page":"e20266","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 KDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS One"},{"key":"2025030500175247600_keae614-B67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CND.0000000000000353","article-title":"Diagnostic accuracy of anti-CN1A on the diagnosis of inclusion body myositis. A hierarchical bivariate and Bayesian meta-analysis","volume":"23","author":"Mavroudis","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025030500175247600_keae614-B68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.55563\/clinexprheumatol\/r625rm","article-title":"Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis","volume":"40","author":"Salam","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500175247600_keae614-B69","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025030500175247600_keae614-B70","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/jnnp-2023-331474","article-title":"Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis","volume":"94","author":"Yamashita","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025030500175247600_keae614-B71","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody\u2013positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology"},{"key":"2025030500175247600_keae614-B72","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Krystufkova","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025030500175247600_keae614-B73","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4049\/immunohorizons.2200078","article-title":"The plasma cell infiltrate populating the muscle tissue of patients with inclusion body myositis features distinct B cell receptor repertoire properties","volume":"7","author":"Jiang","year":"2023","journal-title":"Immunohorizons"},{"key":"2025030500175247600_keae614-B74","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/119.6.1887","article-title":"Inclusion body myositis in HIV-1 and HTLV-1 infected patients","volume":"119","author":"Cupler","year":"1996","journal-title":"Brain"},{"key":"2025030500175247600_keae614-B75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/jnen\/nlv023","article-title":"T-cell-mediated inflammatory myopathies in HIV-positive individuals: a histologic study of 19 cases","volume":"75","author":"Hiniker","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025030500175247600_keae614-B76","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000003821","article-title":"Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients","volume":"88","author":"Lloyd","year":"2017","journal-title":"Neurology"},{"key":"2025030500175247600_keae614-B77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2018.01.005","article-title":"Inclusion body myositis and human immunodeficiency virus type 1: a new case report and literature review","volume":"28","author":"Couture","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2025030500175247600_keae614-B78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/nen.0b013e31815f38b7","article-title":"Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan","volume":"67","author":"Matsuura","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025030500175247600_keae614-B79","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1128\/JVI.78.19.10320-10327.2004","article-title":"Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia\/lymphoma virus type 1-infected patient with sporadic inclusion body myositis","volume":"78","author":"Ozden","year":"2004","journal-title":"J Virol"},{"key":"2025030500175247600_keae614-B80","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.ymthe.2017.09.002","article-title":"Unfounded claims of improved functional outcomes attributed to follistatin gene therapy in inclusion body myositis","volume":"25","author":"Greenberg","year":"2017","journal-title":"Mol Ther"},{"key":"2025030500175247600_keae614-B81","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"2025030500175247600_keae614-B82","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"key":"2025030500175247600_keae614-B83","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.26830","article-title":"Inclusion-body myositis and primary Sjogren syndrome: mechanisms for shared etiologies","volume":"61","author":"Limaye","year":"2020","journal-title":"Muscle Nerve"},{"key":"2025030500175247600_keae614-B84","doi-asserted-by":"crossref","first-page":"1153789","DOI":"10.3389\/fimmu.2023.1153789","article-title":"Uncovering the significance of expanded CD8(+) large granular lymphocytes in inclusion body myositis: insights into T cell phenotype and functional alterations, and disease severity","volume":"14","author":"McLeish","year":"2023","journal-title":"Front Immunol"},{"key":"2025030500175247600_keae614-B85","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3324\/haematol.2009.018481","article-title":"Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases","volume":"95","author":"Bareau","year":"2010","journal-title":"Haematologica"},{"key":"2025030500175247600_keae614-B86","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","article-title":"How I treat LGL leukemia","volume":"117","author":"Lamy","year":"2011","journal-title":"Blood"},{"key":"2025030500175247600_keae614-B87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1600-065X.2003.00051.x","article-title":"Activation-induced cell death in T cells","volume":"193","author":"Green","year":"2003","journal-title":"Immunol Rev"},{"key":"2025030500175247600_keae614-B88","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/art.27665","article-title":"Expanded T cell receptor V\u03b2-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells","volume":"62","author":"Pandya","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025030500175247600_keae614-B89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2567.2011.03470.x","article-title":"CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease","volume":"134","author":"Strioga","year":"2011","journal-title":"Immunology"},{"key":"2025030500175247600_keae614-B90","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells","volume":"101","author":"Brenchley","year":"2003","journal-title":"Blood"},{"key":"2025030500175247600_keae614-B91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11357-009-9100-9","article-title":"KLRG1\u2014more than a marker for T cell senescence","volume":"31","author":"Henson","year":"2009","journal-title":"Age (Dordr)"},{"key":"2025030500175247600_keae614-B92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","article-title":"Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025030500175247600_keae614-B93","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4049\/jimmunol.161.2.1018","article-title":"Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients","volume":"161","author":"Schirmer","year":"1998","journal-title":"J Immunol"},{"key":"2025030500175247600_keae614-B94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/intimm\/11.2.229","article-title":"Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones","volume":"11","author":"Posnett","year":"1999","journal-title":"Int Immunol"},{"key":"2025030500175247600_keae614-B95","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.4049\/jimmunol.165.11.6301","article-title":"Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways","volume":"165","author":"Vallejo","year":"2000","journal-title":"J Immunol"},{"key":"2025030500175247600_keae614-B96","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/annrheumdis-2022-eular.2141","article-title":"POS1342 depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM)","volume":"81","author":"Goel","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"2025030500175247600_keae614-B97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molmed.2021.10.003","article-title":"Pathogenic role and therapeutic potential of fibro-adipogenic progenitors in muscle disease","volume":"28","author":"Hogarth","year":"2022","journal-title":"Trends Mol Med"},{"key":"2025030500175247600_keae614-B98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00401-023-02637-2","article-title":"Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis","volume":"146","author":"Nelke","year":"2023","journal-title":"Acta Neuropathol"},{"key":"2025030500175247600_keae614-B99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.stem.2018.12.014","article-title":"Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors","volume":"24","author":"Lukjanenko","year":"2019","journal-title":"Cell Stem Cell"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae614\/61024016\/keae614.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/952\/61024016\/keae614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/952\/61024016\/keae614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:18:48Z","timestamp":1741115928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/952\/7879350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,6]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae614","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,6]]}}}